Molecular Formula | C27H35ClN2O7 |
Molar Mass | 535.03 |
Melting Point | 141-1610C |
Boling Point | 709.3°C at 760 mmHg |
Specific Rotation(α) | D23 +34.2° (c = 1.1 in ethanol) |
Flash Point | 382.8°C |
Solubility | DMSO 20 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Vapor Presure | 4.1E-21mmHg at 25°C |
Appearance | powder |
Storage Condition | 2-8°C |
MDL | MFCD00940481 |
Use | Moexipril HCl is a potent orally active non sulfhydryl angiotensin converting enzyme(ACE) inhibitor |
In vitro study | Moexipril dose-dependently reduced the percentage of injured neurons, as well as glutamate, staurosporine, or ferric ion-induced mitochondrial reactive oxygen species production. Moexipril and Enalapril attenuated staurosporine-induced neuronal apoptosis, as determined by nuclear staining of hoechst33258. |
In vivo study | As compared to control mice, Moexipril(0.3 mg/kg) significantly reduced brain injury after focal ischemia. In a rat model of cerebral ischemia, Moexipril(0.01 mg/kg) reduced infarct volume. In the tibia of ovariectomized (OVX) spontaneously hypertensive rats (SHR), Moexipril lowers blood pressure. The combination of Moexipril and hydrochrothiazide (HCTZ) showed a more powerful blood pressure lowering effect, with the same effect on bone mass and dynamic endpoints. In rabbit lung, Moexiprilat showed a greater inhibitory effect on plasma ACE and purified ACE than enalaprilat. Moexipril(0.1-30 mg/kg/day) lowered blood pressure and inhibited ACE activity in plasma, lung, aorta, heart, and kidney in a dose-dependent manner. Moexipril(10 mg/kg/day) caused a decrease in blood pressure, inhibited plasma ACE and reduced plasma angiotensinogen, attenuated the pressure response of angiotensin I and the hypotensive response of bradykinin. |
Hazard Symbols | N - Dangerous for the environment |
Risk Codes | 50 - Very Toxic to aquatic organisms |
Safety Description | 60 - This material and its container must be disposed of as hazardous waste. |
UN IDs | UN 3077 9/PG 3 |
WGK Germany | 3 |
RTECS | NW7174500 |
HS Code | 2933492250 |
biological activity | moexibril HCl (RS-10085) is an orally effective non-thiol angiotensin converting enzyme (ACE) inhibitor, the IC50 is 0.041 µm and is indicated for the treatment of hypertension and congestive heart failure. |
Target | Value |
ACE |